Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00366691
Other study ID # MRC-06-002
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 2006
Est. completion date September 2007

Study information

Verified date June 2006
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.


Description:

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAIDs) which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis (cyclo-oxigenase inhibitors). However, they leave the lipoxygenase pathway free to generate leukotrienes. This pharmacodynamic activity has been speculated as a reason why NSAIDs produce less ocular side effects than corticosteroids. It has been widely used in ophthalmology. In 1987, Flach1 published its effectiveness in the treatment of aphakic and pseudophakic macular edema. Its efficacy after cataract surgery has been shown2 and it has been compared to topical steroids after extra-capsular cataract extraction3,4,5 and phacoemulsification6,7. It has been used as analgesic after radial keratotomy(RK)8,9, photorefractive keratectomy (PRK)10 and laser in situ keratomileusis (LASIK)11

The purpose of this study is to compare the effectiveness of the NSAID ketorolac tromethamine ophthalmic solution 0.4% with the steroid loteprednol etabonate ophthalmic suspension 0.5% for preventing anterior segment inflammation after routine cataract surgery.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject must have a visually significant age-related cataract, in the planned operated eye.

- 18 years of age or older.

- The vision in the fellow, unoperated eye should have a potential visual acuity of 20/40 or better as determined by the principal investigator.

- Patient must desire cataract extraction.

- Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

- Advanced glaucomatous damage.

- Any abnormality preventing reliable applanation tonometry in operated eye.

- Contact lens use during the active treatment portion of the trial in the operated eye.

- Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in either eye.

- Any history of allergic hypersensitivity or poor tolerance to any component of the preparations used in this trial.

- Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control.

- Any clinically significant, serious or severe medical or psychiatric condition.

- Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial.

- Intraocular conventional surgery within the past three months or intraocular laser surgery within one month in the operated eye.

- Required use of other topical medications during the active portion of the trial except prophylactic antibiotic, topical lid care, tear replacement solutions or glaucoma medications.

- Other ocular surgery at the time of the cataract extraction.

- Use of topical or oral antiprostaglandins or corticosteroids as well as aspirin products (> 81 mg) during the active treatment portion of the trial. If patient wants to participate in the trial and can stop the medication, he/she can be enrolled after 7-day wash out period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acular LS

Lotemax


Locations

Country Name City State
United States Storm Eye Institute, Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT00924729 - Study of Ocular Penetration of Topically Administered Fluoroquinolones Phase 4
Completed NCT00524264 - A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery Phase 3
Completed NCT00521456 - A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery Phase 3
Completed NCT00565695 - Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction N/A
Completed NCT02973880 - Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction Phase 3
Completed NCT00721695 - Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification. Phase 1/Phase 2
Withdrawn NCT00466908 - Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery
Completed NCT00366665 - Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems N/A
Completed NCT05571683 - Cerebral Oxymeter and End Tidal Carbondioxide Values Under Surgical Drapes With and Without Past COVID-19 Infection
Not yet recruiting NCT04977115 - Clinical Evaluation of Intraocular Caliper-assisted Capsulotomy for Age-related Cataract N/A
Withdrawn NCT00366613 - Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation Phase 4
Completed NCT00366496 - Surgical Outcomes After Routine Cataract Extraction & Implantation of a Conventional or Spheric Intraocular Lens N/A
Not yet recruiting NCT03828500 - Preoperative Fasting for Ambulatory Cataract Surgery: The PRACTICE Study N/A
Completed NCT00840580 - Effect on Wound Healing of Vigamox Versus Cravit Phase 4
Completed NCT00842231 - Assessment of Visual Performance in Patients With Low Levels of Astigmatism N/A
Completed NCT00851760 - Epiretinal Macular Membrane and Cataract Extraction N/A
Recruiting NCT03944070 - Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery N/A
Completed NCT03364972 - A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00 N/A
Completed NCT00824070 - Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Phase 1
Completed NCT00366405 - Comparison of the Torsional Handpiece to Conventional Handpiece During Routine Phacoemulsification Phase 4